公开(公告)号：US11324736B2

公开(公告)日：2022-05-10

申请号：US16946402

申请日：2020-06-19

Applicant: ChemoCentryx, Inc.

Inventor： Zhenhua Miao ,  Thomas Schall ,  Rajinder Singh

IPC: A61K31/444 ,  A61K35/545 ,  A61K31/519 ,  A61K31/4184 ,  A61K31/403 ,  A61K31/4422 ,  A61K31/4178 ,  A61K39/395 ,  A61K31/7034 ,  A61K31/28 ,  A61K31/4418 ,  A61K31/137 ,  A61K31/44 ,  A61K31/426 ,  A61P13/12

Abstract: A method of treating focal segmental glomerulosclerosis with a compound of Formula I is provided. FSGS may be primary (no known cause) or secondary. The secondary FSGS may be associated with infections or viruses such as HIV, diseases such as sickle cell disease or lupus, toxins or drugs such as anabolic steroids, heroin or pamidronate, nephron loss and hyperfiltration, such as with chronic pyelonephritis and reflux, morbid obesity, or diabetes mellitus.

公开(公告)号：US20220125775A1

公开(公告)日：2022-04-28

申请号：US17512335

申请日：2021-10-27

Applicant: CHEMOCENTRYX, INC.

Inventor： Shijie LI ,  Rajinder Singh ,  Thomas J. Schall ,  Peter Staehr

IPC: A61K31/451 ,  A61P17/00

Abstract: Provided herein are methods for treating a subject suffering from a cutaneous neutrophilic inflammatory disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein each variable position is as defined herein. In some embodiments, the cutaneous neutrophilic inflammatory disease is Hidradenitis suppurativa (HS).

公开(公告)号：US11266643B2

公开(公告)日：2022-03-08

申请号：US16874212

申请日：2020-05-14

Applicant: CHEMOCENTRYX, INC.

Inventor： Pingchen Fan ,  Christopher Lange ,  Venkat Reddy Mali ,  Darren J. McMurtrie ,  Viengkham Malathong ,  Sreenivas Punna ,  Rajinder Singh ,  Ju Yang ,  Yibin Zeng ,  Penglie Zhang

IPC: C07D405/12 ,  A61K31/4985 ,  C07D471/04 ,  C07D401/12 ,  A61K31/506 ,  C07D403/12

Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1a, R1b, R1c, R1d, R2a, R2b, R3, R3a, R4, R6, R7, R8, A, Z, X1 and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

公开(公告)号：US10973809B2

公开(公告)日：2021-04-13

申请号：US15821490

申请日：2017-11-22

Applicant: ChemoCentryx, Inc.

Inventor： Zhenhua Miao ,  Thomas Schall ,  Rajinder Singh

IPC: A61K31/444 ,  A61K35/545 ,  A61K31/519 ,  A61K31/4184 ,  A61K31/403 ,  A61K31/4422 ,  A61K31/4178 ,  A61K39/395 ,  A61K31/7034 ,  A61K31/28 ,  A61K31/4418 ,  A61K31/137 ,  A61K31/44 ,  A61K31/426 ,  A61P13/12

Abstract: A method of treating focal segmental glomerulosclerosis with a compound of Formula I is provided. FSGS may be primary (no known cause) or secondary. The secondary FSGS may be associated with infections or viruses such as HIV, diseases such as sickle cell disease or lupus, toxins or drugs such as anabolic steroids, heroin or pamidronate, nephron loss and hyperfiltration, such as with chronic pyelonephritis and reflux, morbid obesity, or diabetes mellitus.

公开(公告)号：US10759789B2

公开(公告)日：2020-09-01

申请号：US16524618

申请日：2019-07-29

Applicant: CHEMOCENTRYX, INC.

Inventor： Xi Chen ,  Dean R. Dragoli ,  Pingchen Fan ,  Manmohan Reddy Leleti ,  Rebecca M. Lui ,  Viengkham Malathong ,  Jay P. Powers ,  Rajinder Singh ,  Hiroko Tanaka ,  Ju Yang ,  Chao Yu ,  Penglie Zhang

IPC: A61K31/404 ,  A61K31/4439 ,  C07D405/14 ,  C07D405/04 ,  C07D401/04 ,  C07D209/34 ,  A61P1/00 ,  A61P19/00 ,  A61P17/00 ,  A61P35/00 ,  A61P11/00

Abstract: Oxindole compounds useful for the treatment of CCR(9) mediated conditions or diseases are provided.

公开(公告)号：US10568874B2

公开(公告)日：2020-02-25

申请号：US16281448

申请日：2019-02-21

Applicant: CHEMOCENTRYX, INC.

Inventor： Christopher Lange ,  Sreenivas Punna ,  Rajinder Singh ,  Ju Yang ,  Penglie Zhang

IPC: C07C229/22 ,  A61K31/445 ,  A61K31/198 ,  A61K31/454 ,  A61K45/06 ,  C07D401/12 ,  A61K31/4545 ,  C07D211/92

Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2a, R2b, R2c, R3, R4, R5, R6a, R6b, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

公开(公告)号：US12011439B2

公开(公告)日：2024-06-18

申请号：US17820179

申请日：2022-08-16

Applicant: CHEMOCENTRYX, INC.

Inventor： Shijie Li ,  Venkat Reddy Mali ,  Rajinder Singh ,  Ju Yang ,  Penglie Zhang

IPC: A61K31/4545 ,  A61K31/165 ,  A61K31/357 ,  A61K39/395 ,  A61P35/00

CPC classification number: A61K31/4545 ,  A61K31/165 ,  A61K31/357 ,  A61K39/39541 ,  A61P35/00

Abstract: The present disclosure is drawn to the combination therapy of a C-C Chemokine Receptor 4 (CCR4) antagonist and one or more immune checkpoint inhibitors in the treatment of cancer.

公开(公告)号：US11986466B2

公开(公告)日：2024-05-21

申请号：US17128500

申请日：2020-12-21

Applicant: CHEMOCENTRYX, INC. ,  THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Inventor： James J. Campbell ,  Rajinder Singh ,  Samuel Hwang ,  Xuesong Wu

IPC: A61K31/4433 ,  A61K31/496 ,  A61K39/395 ,  A61P35/00 ,  C07K16/28

CPC classification number: A61K31/4433 ,  A61K31/496 ,  A61K39/39533 ,  A61P35/00 ,  C07K16/2818 ,  C07K16/2827 ,  A61K39/39533 ,  A61K2300/00

Abstract: The present disclosure provides, inter alia, methods of treating a solid-tumor by administering an effective amount of a Chemokine Receptor 2 (CCR2) antagonist. Also provided herein are methods of reducing the number of macrophages in a solid tumor microenvironment, said method comprising administering effective amount of a Chemokine Receptor 2 (CCR2) antagonist. In an additional aspect, the current disclosure further provides methods of increasing the number CD8+ T cells in a solid tumor microenvironment, said method comprising administering effective amount of a Chemokine Receptor 2 (CCR2) antagonist. In some embodiments, the CCR2 antagonist has the formula I or Formula III:

公开(公告)号：US11844790B2

公开(公告)日：2023-12-19

申请号：US17512335

申请日：2021-10-27

Applicant: CHEMOCENTRYX, INC.

Inventor： Shijie Li ,  Rajinder Singh ,  Thomas J. Schall ,  Peter Staehr

IPC: A61K31/451 ,  A61P17/00

CPC classification number: A61K31/451 ,  A61P17/00

Abstract: Provided herein are methods for treating a subject suffering from a cutaneous neutrophilic inflammatory disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I




or a pharmaceutically acceptable salt thereof, wherein each variable position is as defined herein. In some embodiments, the cutaneous neutrophilic inflammatory disease is Hidradenitis suppurativa (HS).

公开(公告)号：US11759458B2

公开(公告)日：2023-09-19

申请号：US17460716

申请日：2021-08-30

Applicant: CHEMOCENTRYX, INC.

Inventor： Christopher Lange ,  Sreenivas Punna ,  Rajinder Singh ,  Ju Yang ,  Penglie Zhang

IPC: A61K31/445 ,  C07C229/22 ,  A61K31/198 ,  A61K31/454 ,  A61K45/06 ,  C07D401/12 ,  A61K31/4545 ,  C07D211/92

CPC classification number: A61K31/445 ,  A61K31/198 ,  A61K31/454 ,  A61K31/4545 ,  A61K45/06 ,  C07C229/22 ,  C07D211/92 ,  C07D401/12

Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I)




including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2a, R2b, R2c, R3, R4, R5, R6a, R6b, m and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.